B. Metzler seel. Sohn & Co’s Dyne Therapeutics DYN Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-19,962	Closed	-$265K	–	760
2023 Q4	$265K	Buy	19,962 +989	+5%	+$9.66K	﹤0.01%	699
2023 Q3	$170K	Sell	18,973 -18,973	-50%	-$204K	﹤0.01%	716
2023 Q2	$427K	Buy	37,946 +18,973	+100%	+$224K	0.01%	597
2023 Q1	$219K	Buy	18,973 +3,436	+22%	+$44.6K	﹤0.01%	693
2022 Q4	$180K	Buy	15,537 +2,933	+23%	+$33.9K	﹤0.01%	709
2022 Q3	$160K	Buy	+12,604	New	+$145K	﹤0.01%	718

Other funds holding DYN

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

B. Metzler seel. Sohn & Co's DYN Position: Q1 2024 in Review

B. Metzler seel. Sohn & Co sold out of Dyne Therapeutics (DYN) in Q1 2024, closing a stake of 19,962 shares — an estimated $265K sold.

B. Metzler seel. Sohn & Co first reported a position in DYN in Q3 2022 and held it in 6 quarters. The position peaked at $427K in Q2 2023. 169 funds tracked by Wall St. Rank hold DYN as of Q1 2024.

B. Metzler seel. Sohn & Co reported no remaining Dyne Therapeutics position as of Q1 2024 after selling out during the quarter.
B. Metzler seel. Sohn & Co sold 19,962 Dyne Therapeutics shares in Q1 2024, an estimated $265K.
B. Metzler seel. Sohn & Co first reported a position in Dyne Therapeutics in Q3 2022 and held it in 6 quarters.
B. Metzler seel. Sohn & Co's Dyne Therapeutics position peaked at $427K in Q2 2023.
169 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2024.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q1 2024, filed 15 May 2024.